Finland: Faron tops up working capital with private placement

Faron Pharmaceuticals, a Finland-based clinical stage biopharmaceutical company harnessing the immune system to tackle cancer and inflammation, has completed a private placement of 2,006,621 newly issued treasury shares to a limited number of institutional investors and other investors, raising €5m (US$5.3m). “This fundraise will enable us to accelerate our ambitious bexmarilimab development programme, with a…

You must be a HMI Subscriber to view this content.

Subscribe Now »